Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Glyoxalase 1 gene expression in various types of cancer cells immunopathology: a pan-cancer analysis study

Alaseem AM., Aldali JA., Alasiri G., Alhujaily M., AlHussaini KI., AlKhamees OA.

Laboratory Study on Immune Modulation, published in Front Oncol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Oncol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40727469
PMCID
PMC12301202
DOI
10.3389/fonc.2025.1610886

Abstract (original English)

Metabolic reprogramming within the tumor microenvironment significantly affects cancer progression by shifting toward aerobic glycolysis and lactate production, while also supporting mitochondrial oxidative phosphorylation. The glyoxalase system, comprising GLO-1 and GLO-2, maintains metabolic homeostasis by neutralizing methylglyoxal (MG) byproducts. GLO-1 protects cells from damage by detoxifying MG via glutathione. In the curent study, pan-cancer analysis revealed elevated GLO-1 mRNA levels across various malignancies, exhibiting variable prognostic implications on patient survival: reduced survival in ACC, MESO, and SARC, and enhanced survival in KIRC and LIHC. GLO-1 activity is regulated by transcriptional and post-translational modifications, including phosphorylation, NO-mediated modification, and glutathionylation. The role of GLO-1 in survival and disease course differs depending on the specific cancer. GLO-1 levels were associated with immunotherapy markers like microsatellite instability (MSI) and tumor mutational burden (TMB), with positive correlations between GLO-1 and MSI in UCEC, TGCT, and STAD, and between GLO-1 and TMB in LUAD, UCEC, LIHC, MESO, SKCM, and READ. In terms of immune cell presence, GLO-1 was associated with increased endothelial and neutrophil cells, decreased T and B cell populations, and increased activated CD4 T cells, memory B cells, and type

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research